Amgen gets FDA OK to market Repatha's ability to prevent heart attacks

You are here: Home > Central Coast Health Watch > Current Article

Amgen gets FDA OK to market Repatha’s ability to prevent heart attacks

By Staff Report / Friday, December 1st, 2017 / Comments Off on Amgen gets FDA OK to market Repatha’s ability to prevent heart attacks

The U.S Food and Drug Administration gave Thousand Oaks biotech giant Amgen the go-ahead to market its cholesterol drug Repatha to patients at risk of a heart attack or stroke. Shares for the company rose around 1 percent after the news, ending at $177.51 in after-hours trading. The drug brought in around $58 million for…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.